Chief Scientist / GlaxoSmithKline Vaccines
Dr. Rappuoli is known globally for his work in vaccines and immunology — he co-founded the field of cellular microbiology and pioneered the genomic approach to vaccine development known as reverse vaccinology. He is also the Founder of the GSK Vaccines Institute for Global Health.
During his scientific career, Dr. Rappuoli introduced novel scientific concepts of genetic detoxification, cellular microbiology, reverse vaccinology and pangenome.
Dr. Rappuoli also developed a number of licensed vaccines — acellular pertussis containing a non-toxic mutant of pertussis toxin; the first conjugate vaccine against meningococcus C and the first vaccine for meningococcus B, for which both vaccines the United Kingdom has been forerunner in introducing them for mass immunization; MF59, the first vaccine adjuvant after aluminium salts; CRM197 that is used as carrier in many conjugate vaccines.